St. Paul Global Week brings pilgrims to Tarsus, Türkiye, from 28 to 30 June 2027 for a three-day gathering in the Apostle ...

The mouthparts of an adult female blacklegged tick, also known as a deer tick. The outer protrusions are used to secure a ...

Tarsus Pharmaceuticals is fronting $450 million to acquire Alkeus Pharmaceuticals for its phase 3 retinal disease therapy, touted as a potential blockbuster. In return for $270 million in cash and ...

Tarsus has agreed to buy Alkeus in an $800 million deal that will give it rights to a drug for rare eye disorder Stargardt disease that has "blockbuster potential." The takeover revolves around Alkeus ...

Tarsus Pharmaceuticals (TARS) agreed to acquire privately held Alkeus Pharmaceuticals, gaining gildeuretinol (ALK-001), an investigational once-daily oral therapy for Stargardt disease, a rare ...

Aug 6 (Reuters) - Eye drugmaker Tarsus Pharmaceuticals (TARS.O), opens new tab said on Thursday it would acquire privately held Alkeus Pharmaceuticals in a ‌cash-and-stock deal worth up to $800 ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

IRVINE, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (“Tarsus”) today announced that it has entered into a securities purchase agreement with certain qualified ...

Bobak Azamian (Co-Founder, President, CEO & Chairman) said, "Today is an important day for Tarsus. We're reporting another exceptional quarter for XDEMVY and announcing the acquisition of Alkeus ...

Adds a potential blockbuster opportunity with gildeuretinol (ALK-001), a differentiated Phase 3 oral investigational medicine designed to target the underlying biology of Stargardt disease, one of the ...

Transaction structure includes $270 million cash, $180 million equity at $61.38/share, up to $350 million milestones, and low single-digit tiered descending royalties on net sales. Mechanistic ...